Page last updated: 2024-11-08

vinblastine sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID241902
CHEMBL ID376464
CHEBI ID9984
SCHEMBL ID3550
MeSH IDM0373265
PubMed CID5388983
CHEMBL ID378544
SCHEMBL ID3549
MeSH IDM0373265

Synonyms (112)

Synonym
v1193 ,
belvan, vlb
vincaleukoblastine sulfate
vincaleukoblastine, monohydrate
vinblastine, hydrate
vincaleucoblastine sulfate
wln: t c6 b5665/bs 2ab s bx in qn nu & & tttj fo1 i1 kvo1 kq lov1 m2 e-ct f6 d596a en on & & ttj cvo1 q
vincaleukoblastine sulfate (1:1) (salt)
wln: t c6 b5665/bs 2ab s bx in qn nu & & tttj fo1 i1 kvo1 kq lov1 m2 e-ct f6d596a en on & & ttj cvo1 q
vinblastine sulfate hydrate
vlb monosulfate
velban (tn) (lilly)
vincaleukoblastine, hydrate
CHEBI:9984 ,
vinblastine 5
NSC49842 ,
vinblastine sulfate (jp17/usp)
exal (tn)
D01068
velban (tn)
vinblastine sulphate
CHEMBL376464
vincaleukoblastine sulfate salt
FT-0603354
SCHEMBL3550
AKOS024456494
mfcd08706468
KDQAABAKXDWYSZ-JKDPCDLQSA-N
HMS3676C14
Q27108547
AS-12480
HMS3412C14
MLS002207069
MLS002153253
exal
nsc-49842
29060-le
velbe
29060 le
velsar
vinblastine sulfate salt, powder, >=96% (hplc)
vincaleukoblastine, sulfate (1:1) (salt)
MLS000863275 ,
ai3-52943
ccris 2584
einecs 205-606-0
vincaleukoblastine, sulfate
rozevin sulfate
smr000058844
MLS000069550
sulfate, vinblastine
AC-821
29060le
CHEMBL378544 ,
vinblastini sulfas
alkaban-aq
unii-n00w22yo2b
n00w22yo2b ,
vinblastine sulfate [usan:usp:jan]
uniblastin
cas-18556-44-0
tox21_112735
dsstox_gsid_47853
dsstox_rid_82594
tox21_111498
dsstox_cid_27831
HMS2235E07
AKOS015960580
HY-13780
vinblastine (sulfate)
CS-1365
vinblastine sulfate [mi]
vinblastine sulfate [ep monograph]
vinblastine sulfate [vandf]
vinblastine sulfate [usan]
vinblastine sulfate [iarc]
vinblastine sulfate [mart.]
vinblastini sulfas [who-ip latin]
vinblastine sulfate [usp-rs]
vinblastine sulfate [jan]
vinblastine sulfate [usp monograph]
vinblastine sulfate [orange book]
vinblastine sulfate [who-dd]
vinblastine sulfate [who-ip]
SCHEMBL3549
tox21_112735_1
tox21_111498_1
NCGC00344583-01
NCGC00263548-01
KDQAABAKXDWYSZ-PNYVAJAMSA-N
HMS3403N09
OPERA_ID_960
sr-01000000155
SR-01000000155-7
methyl (1r,9r,10s,11r,12r,19r)-11-(acetyloxy)-12-ethyl-4-[(13s,15r,17s)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0?,??.0?,??]nonadeca-4(12),5(10),6,8-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0?,?
vinblastine sulfate, united states pharmacopeia (usp) reference standard
methyl (1r,9r,10s,11r,12r,19r)-11-(acetyloxy)-12-ethyl-4-[(13s,15r,17s)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5(10),6,8-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.
EN300-1268144
vinblastine sulfate, european pharmacopoeia (ep) reference standard
methyl (3ar,3a1r,4r,5s,5ar,10br)-4-acetoxy-3a-ethyl-9-((5s,7r,9s)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2h-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1h-indolizi
Q27077057
DTXSID601017133 ,
vincaleukoblastine,sulfate(1:1)
vinblastinesulfate
Z3014322079
dtxcid7027831
vinblastine sulfate (usp monograph)
vinblastine sulfate (iarc)
vinblastine sulfate (mart.)
methyl (3ar,4r,5s,5ar,10br,13ar)-4-acetoxy-3a-ethyl-9-((5s,7r,9s)-5-ethyl-5-hydroxy-9-methoxycarbonyl-1,4,5,6,7,8,9,10-octahydro-3,7-methano-3-azacycloundecino(5,4-b)indol-9-yl)-5-hydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-1h-indolizino(8,
vinblastine sulfate (ep monograph)
vinblastine sulfate (usp-rs)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkaloid sulfate salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (74)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency8.91250.044717.8581100.0000AID485341
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency15.84890.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency28.18380.125919.1169125.8920AID2549
thioredoxin reductaseRattus norvegicus (Norway rat)Potency50.11870.100020.879379.4328AID588453
RAR-related orphan receptor gammaMus musculus (house mouse)Potency2.76540.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency18.68130.173734.304761.8120AID1346859; AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency0.37400.004110.890331.5287AID504466; AID504467
SMAD family member 3Homo sapiens (human)Potency18.68130.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency0.07520.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.09160.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency28.18380.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency12.98350.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063
Smad3Homo sapiens (human)Potency4.46680.00527.809829.0929AID588855
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency0.03160.00137.762544.6684AID914; AID915
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency23.71010.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.20100.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency15.09210.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency9.12050.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.12710.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency2.26090.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency4.58520.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency8.61980.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency10.83280.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency4.08410.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.04830.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency22.45860.00108.379861.1304AID1645840
67.9K proteinVaccinia virusPotency8.55390.00018.4406100.0000AID720579; AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency2.98470.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency7.91200.001019.414170.9645AID743094; AID743140
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency29.30100.023723.228263.5986AID743222; AID743241
IDH1Homo sapiens (human)Potency0.08200.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency35.48130.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency27.31160.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency1.14840.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency3.010719.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.23310.057821.109761.2679AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency5.38080.10009.191631.6228AID1346983
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency1.00000.01262.451825.0177AID485313
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.23110.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.06690.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency31.66790.042027.378961.6448AID743210; AID743228
huntingtin isoform 2Homo sapiens (human)Potency0.11220.000618.41981,122.0200AID1688
ras-related protein Rab-9AHomo sapiens (human)Potency0.31620.00022.621531.4954AID485297
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.26340.000627.21521,122.0200AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency50.11870.425612.059128.1838AID504891
gemininHomo sapiens (human)Potency0.01460.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency2.81840.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency1.98460.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency3.32940.00339.158239.8107AID1347407
Cellular tumor antigen p53Homo sapiens (human)Potency0.02410.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency1.98460.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.79450.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency0.72720.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin beta-4A chainHomo sapiens (human)IC50 (µMol)0.15000.00051.968010.0000AID1492876
Tubulin beta chainHomo sapiens (human)IC50 (µMol)0.15000.00052.052910.0000AID1492876
Tubulin alpha-3C chainHomo sapiens (human)IC50 (µMol)0.15000.00051.955510.0000AID1492876
Tubulin alpha-1B chainHomo sapiens (human)IC50 (µMol)0.15000.00051.955510.0000AID1492876
Tubulin alpha-4A chainHomo sapiens (human)IC50 (µMol)0.15000.00051.955510.0000AID1492876
Tubulin beta-4B chainHomo sapiens (human)IC50 (µMol)0.15000.00051.968010.0000AID1492876
Tubulin beta-3 chainHomo sapiens (human)IC50 (µMol)0.15000.00051.894510.0000AID1492876
Tubulin beta-2A chainHomo sapiens (human)IC50 (µMol)0.15000.00051.968010.0000AID1492876
Tubulin beta-8 chainHomo sapiens (human)IC50 (µMol)0.15000.00051.968010.0000AID1492876
Tubulin alpha-3E chainHomo sapiens (human)IC50 (µMol)0.15000.00051.955510.0000AID1492876
Tubulin alpha-1A chainHomo sapiens (human)IC50 (µMol)0.15000.00051.955510.0000AID1492876
Tubulin alpha-1C chainHomo sapiens (human)IC50 (µMol)0.15000.00051.955510.0000AID1492876
Tubulin beta-6 chainHomo sapiens (human)IC50 (µMol)0.15000.00051.968010.0000AID1492876
Tubulin beta-2B chainHomo sapiens (human)IC50 (µMol)0.15000.00051.968010.0000AID1492876
Tubulin beta-1 chainHomo sapiens (human)IC50 (µMol)0.15000.00051.987010.0000AID1492876
nuclear receptor subfamily 0 group B member 1Homo sapiens (human)IC50 (µMol)67.54100.13430.86462.1450AID687017
steroidogenic factor 1Homo sapiens (human)IC50 (µMol)67.54101.87302.92953.9860AID687018
Tubulin alpha-1A chainSus scrofa (pig)IC50 (µMol)0.13000.00672.160310.0000AID159533; AID274785; AID303685; AID347582; AID494502; AID605956; AID611278
Tubulin beta chainSus scrofa (pig)IC50 (µMol)0.13000.00672.137410.0000AID159533; AID274785; AID303685; AID347582; AID494502; AID605956; AID611278
Tubulin beta-4A chainHomo sapiens (human)IC50 (µMol)0.13000.00051.968010.0000AID494521
Tubulin beta chainHomo sapiens (human)IC50 (µMol)0.13000.00052.052910.0000AID494521
Tubulin alpha-3C chainHomo sapiens (human)IC50 (µMol)0.13000.00051.955510.0000AID494521
Tubulin alpha-1B chainHomo sapiens (human)IC50 (µMol)0.13000.00051.955510.0000AID494521
Tubulin alpha-4A chainHomo sapiens (human)IC50 (µMol)0.13000.00051.955510.0000AID494521
Tubulin beta-4B chainHomo sapiens (human)IC50 (µMol)0.13000.00051.968010.0000AID494521
Tubulin beta-3 chainHomo sapiens (human)IC50 (µMol)0.13000.00051.894510.0000AID494521
Tubulin beta-2A chainHomo sapiens (human)IC50 (µMol)0.13000.00051.968010.0000AID494521
Tubulin beta-8 chainHomo sapiens (human)IC50 (µMol)0.13000.00051.968010.0000AID494521
Tubulin alpha-3E chainHomo sapiens (human)IC50 (µMol)0.13000.00051.955510.0000AID494521
Tubulin alpha-1A chainHomo sapiens (human)IC50 (µMol)0.13000.00051.955510.0000AID494521
Tubulin alpha-1C chainHomo sapiens (human)IC50 (µMol)0.13000.00051.955510.0000AID494521
Tubulin beta-6 chainHomo sapiens (human)IC50 (µMol)0.13000.00051.968010.0000AID494521
Tubulin beta-2B chainHomo sapiens (human)IC50 (µMol)0.13000.00051.968010.0000AID494521
Tubulin beta-1 chainHomo sapiens (human)IC50 (µMol)0.13000.00051.987010.0000AID494521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PAX8Homo sapiens (human)AC500.26000.04885.435469.1700AID687027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (220)

Processvia Protein(s)Taxonomy
negative regulation of microtubule polymerizationTubulin beta-4A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-4A chainHomo sapiens (human)
mitotic cell cycleTubulin beta-4A chainHomo sapiens (human)
odontoblast differentiationTubulin beta chainHomo sapiens (human)
microtubule-based processTubulin beta chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin beta chainHomo sapiens (human)
natural killer cell mediated cytotoxicityTubulin beta chainHomo sapiens (human)
regulation of synapse organizationTubulin beta chainHomo sapiens (human)
spindle assemblyTubulin beta chainHomo sapiens (human)
cell divisionTubulin beta chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta chainHomo sapiens (human)
mitotic cell cycleTubulin beta chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-3C chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-3C chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1B chainHomo sapiens (human)
microtubule-based processTubulin alpha-1B chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1B chainHomo sapiens (human)
cell divisionTubulin alpha-1B chainHomo sapiens (human)
cellular response to interleukin-4Tubulin alpha-1B chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-4A chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-4A chainHomo sapiens (human)
natural killer cell mediated cytotoxicityTubulin beta-4B chainHomo sapiens (human)
mitotic cell cycleTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-3 chainHomo sapiens (human)
axon guidanceTubulin beta-3 chainHomo sapiens (human)
netrin-activated signaling pathwayTubulin beta-3 chainHomo sapiens (human)
dorsal root ganglion developmentTubulin beta-3 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-3 chainHomo sapiens (human)
cerebral cortex developmentTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-2A chainHomo sapiens (human)
mitotic cell cycleTubulin beta-2A chainHomo sapiens (human)
oocyte maturationTubulin beta-8 chainHomo sapiens (human)
spindle assembly involved in female meiosisTubulin beta-8 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-8 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-8 chainHomo sapiens (human)
biological_processTubulin alpha-3E chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-3E chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-3E chainHomo sapiens (human)
neuron migrationTubulin alpha-1A chainHomo sapiens (human)
startle responseTubulin alpha-1A chainHomo sapiens (human)
intracellular protein transportTubulin alpha-1A chainHomo sapiens (human)
microtubule-based processTubulin alpha-1A chainHomo sapiens (human)
centrosome cycleTubulin alpha-1A chainHomo sapiens (human)
smoothened signaling pathwayTubulin alpha-1A chainHomo sapiens (human)
memoryTubulin alpha-1A chainHomo sapiens (human)
adult locomotory behaviorTubulin alpha-1A chainHomo sapiens (human)
visual learningTubulin alpha-1A chainHomo sapiens (human)
response to mechanical stimulusTubulin alpha-1A chainHomo sapiens (human)
glial cell differentiationTubulin alpha-1A chainHomo sapiens (human)
gene expressionTubulin alpha-1A chainHomo sapiens (human)
dentate gyrus developmentTubulin alpha-1A chainHomo sapiens (human)
cerebellar cortex morphogenesisTubulin alpha-1A chainHomo sapiens (human)
pyramidal neuron differentiationTubulin alpha-1A chainHomo sapiens (human)
cerebral cortex developmentTubulin alpha-1A chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1A chainHomo sapiens (human)
response to tumor necrosis factorTubulin alpha-1A chainHomo sapiens (human)
locomotory exploration behaviorTubulin alpha-1A chainHomo sapiens (human)
microtubule polymerizationTubulin alpha-1A chainHomo sapiens (human)
forebrain morphogenesisTubulin alpha-1A chainHomo sapiens (human)
homeostasis of number of cells within a tissueTubulin alpha-1A chainHomo sapiens (human)
regulation of synapse organizationTubulin alpha-1A chainHomo sapiens (human)
synapse organizationTubulin alpha-1A chainHomo sapiens (human)
cell divisionTubulin alpha-1A chainHomo sapiens (human)
neuron apoptotic processTubulin alpha-1A chainHomo sapiens (human)
motor behaviorTubulin alpha-1A chainHomo sapiens (human)
cellular response to calcium ionTubulin alpha-1A chainHomo sapiens (human)
organelle transport along microtubuleTubulin alpha-1A chainHomo sapiens (human)
neuron projection arborizationTubulin alpha-1A chainHomo sapiens (human)
response to L-glutamateTubulin alpha-1A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1A chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1A chainHomo sapiens (human)
microtubule-based processTubulin alpha-1C chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1C chainHomo sapiens (human)
cell divisionTubulin alpha-1C chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1C chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1C chainHomo sapiens (human)
mitotic cell cycleTubulin beta-6 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-6 chainHomo sapiens (human)
neuron migrationTubulin beta-2B chainHomo sapiens (human)
microtubule-based processTubulin beta-2B chainHomo sapiens (human)
cerebral cortex developmentTubulin beta-2B chainHomo sapiens (human)
modulation of chemical synaptic transmissionTubulin beta-2B chainHomo sapiens (human)
positive regulation of axon guidanceTubulin beta-2B chainHomo sapiens (human)
embryonic brain developmentTubulin beta-2B chainHomo sapiens (human)
mitotic cell cycleTubulin beta-2B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-2B chainHomo sapiens (human)
platelet formationTubulin beta-1 chainHomo sapiens (human)
thyroid gland developmentTubulin beta-1 chainHomo sapiens (human)
microtubule polymerizationTubulin beta-1 chainHomo sapiens (human)
spindle assemblyTubulin beta-1 chainHomo sapiens (human)
thyroid hormone transportTubulin beta-1 chainHomo sapiens (human)
platelet aggregationTubulin beta-1 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-1 chainHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of microtubule polymerizationTubulin beta-4A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-4A chainHomo sapiens (human)
mitotic cell cycleTubulin beta-4A chainHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
odontoblast differentiationTubulin beta chainHomo sapiens (human)
microtubule-based processTubulin beta chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin beta chainHomo sapiens (human)
natural killer cell mediated cytotoxicityTubulin beta chainHomo sapiens (human)
regulation of synapse organizationTubulin beta chainHomo sapiens (human)
spindle assemblyTubulin beta chainHomo sapiens (human)
cell divisionTubulin beta chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta chainHomo sapiens (human)
mitotic cell cycleTubulin beta chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-3C chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-3C chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1B chainHomo sapiens (human)
microtubule-based processTubulin alpha-1B chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1B chainHomo sapiens (human)
cell divisionTubulin alpha-1B chainHomo sapiens (human)
cellular response to interleukin-4Tubulin alpha-1B chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-4A chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-4A chainHomo sapiens (human)
natural killer cell mediated cytotoxicityTubulin beta-4B chainHomo sapiens (human)
mitotic cell cycleTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-3 chainHomo sapiens (human)
axon guidanceTubulin beta-3 chainHomo sapiens (human)
netrin-activated signaling pathwayTubulin beta-3 chainHomo sapiens (human)
dorsal root ganglion developmentTubulin beta-3 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-3 chainHomo sapiens (human)
cerebral cortex developmentTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-2A chainHomo sapiens (human)
mitotic cell cycleTubulin beta-2A chainHomo sapiens (human)
oocyte maturationTubulin beta-8 chainHomo sapiens (human)
spindle assembly involved in female meiosisTubulin beta-8 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-8 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-8 chainHomo sapiens (human)
biological_processTubulin alpha-3E chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-3E chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-3E chainHomo sapiens (human)
neuron migrationTubulin alpha-1A chainHomo sapiens (human)
startle responseTubulin alpha-1A chainHomo sapiens (human)
intracellular protein transportTubulin alpha-1A chainHomo sapiens (human)
microtubule-based processTubulin alpha-1A chainHomo sapiens (human)
centrosome cycleTubulin alpha-1A chainHomo sapiens (human)
smoothened signaling pathwayTubulin alpha-1A chainHomo sapiens (human)
memoryTubulin alpha-1A chainHomo sapiens (human)
adult locomotory behaviorTubulin alpha-1A chainHomo sapiens (human)
visual learningTubulin alpha-1A chainHomo sapiens (human)
response to mechanical stimulusTubulin alpha-1A chainHomo sapiens (human)
glial cell differentiationTubulin alpha-1A chainHomo sapiens (human)
gene expressionTubulin alpha-1A chainHomo sapiens (human)
dentate gyrus developmentTubulin alpha-1A chainHomo sapiens (human)
cerebellar cortex morphogenesisTubulin alpha-1A chainHomo sapiens (human)
pyramidal neuron differentiationTubulin alpha-1A chainHomo sapiens (human)
cerebral cortex developmentTubulin alpha-1A chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1A chainHomo sapiens (human)
response to tumor necrosis factorTubulin alpha-1A chainHomo sapiens (human)
locomotory exploration behaviorTubulin alpha-1A chainHomo sapiens (human)
microtubule polymerizationTubulin alpha-1A chainHomo sapiens (human)
forebrain morphogenesisTubulin alpha-1A chainHomo sapiens (human)
homeostasis of number of cells within a tissueTubulin alpha-1A chainHomo sapiens (human)
regulation of synapse organizationTubulin alpha-1A chainHomo sapiens (human)
synapse organizationTubulin alpha-1A chainHomo sapiens (human)
cell divisionTubulin alpha-1A chainHomo sapiens (human)
neuron apoptotic processTubulin alpha-1A chainHomo sapiens (human)
motor behaviorTubulin alpha-1A chainHomo sapiens (human)
cellular response to calcium ionTubulin alpha-1A chainHomo sapiens (human)
organelle transport along microtubuleTubulin alpha-1A chainHomo sapiens (human)
neuron projection arborizationTubulin alpha-1A chainHomo sapiens (human)
response to L-glutamateTubulin alpha-1A chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1A chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1A chainHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
microtubule-based processTubulin alpha-1C chainHomo sapiens (human)
cytoskeleton-dependent intracellular transportTubulin alpha-1C chainHomo sapiens (human)
cell divisionTubulin alpha-1C chainHomo sapiens (human)
mitotic cell cycleTubulin alpha-1C chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin alpha-1C chainHomo sapiens (human)
mitotic cell cycleTubulin beta-6 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-6 chainHomo sapiens (human)
neuron migrationTubulin beta-2B chainHomo sapiens (human)
microtubule-based processTubulin beta-2B chainHomo sapiens (human)
cerebral cortex developmentTubulin beta-2B chainHomo sapiens (human)
modulation of chemical synaptic transmissionTubulin beta-2B chainHomo sapiens (human)
positive regulation of axon guidanceTubulin beta-2B chainHomo sapiens (human)
embryonic brain developmentTubulin beta-2B chainHomo sapiens (human)
mitotic cell cycleTubulin beta-2B chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-2B chainHomo sapiens (human)
platelet formationTubulin beta-1 chainHomo sapiens (human)
thyroid gland developmentTubulin beta-1 chainHomo sapiens (human)
microtubule polymerizationTubulin beta-1 chainHomo sapiens (human)
spindle assemblyTubulin beta-1 chainHomo sapiens (human)
thyroid hormone transportTubulin beta-1 chainHomo sapiens (human)
platelet aggregationTubulin beta-1 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (61)

Processvia Protein(s)Taxonomy
GTPase activityTubulin beta-4A chainHomo sapiens (human)
calcium ion bindingTubulin beta-4A chainHomo sapiens (human)
protein bindingTubulin beta-4A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-4A chainHomo sapiens (human)
GTP bindingTubulin beta-4A chainHomo sapiens (human)
GTPase activityTubulin beta chainHomo sapiens (human)
structural molecule activityTubulin beta chainHomo sapiens (human)
protein bindingTubulin beta chainHomo sapiens (human)
protein domain specific bindingTubulin beta chainHomo sapiens (human)
ubiquitin protein ligase bindingTubulin beta chainHomo sapiens (human)
GTPase activating protein bindingTubulin beta chainHomo sapiens (human)
MHC class I protein bindingTubulin beta chainHomo sapiens (human)
protein-containing complex bindingTubulin beta chainHomo sapiens (human)
metal ion bindingTubulin beta chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta chainHomo sapiens (human)
GTP bindingTubulin beta chainHomo sapiens (human)
hydrolase activityTubulin alpha-3C chainHomo sapiens (human)
metal ion bindingTubulin alpha-3C chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-3C chainHomo sapiens (human)
GTP bindingTubulin alpha-3C chainHomo sapiens (human)
double-stranded RNA bindingTubulin alpha-1B chainHomo sapiens (human)
GTPase activityTubulin alpha-1B chainHomo sapiens (human)
structural molecule activityTubulin alpha-1B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
protein bindingTubulin alpha-1B chainHomo sapiens (human)
GTP bindingTubulin alpha-1B chainHomo sapiens (human)
ubiquitin protein ligase bindingTubulin alpha-1B chainHomo sapiens (human)
protein bindingTubulin alpha-4A chainHomo sapiens (human)
hydrolase activityTubulin alpha-4A chainHomo sapiens (human)
protein kinase bindingTubulin alpha-4A chainHomo sapiens (human)
metal ion bindingTubulin alpha-4A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
GTP bindingTubulin alpha-4A chainHomo sapiens (human)
double-stranded RNA bindingTubulin beta-4B chainHomo sapiens (human)
GTPase activityTubulin beta-4B chainHomo sapiens (human)
protein bindingTubulin beta-4B chainHomo sapiens (human)
MHC class I protein bindingTubulin beta-4B chainHomo sapiens (human)
metal ion bindingTubulin beta-4B chainHomo sapiens (human)
unfolded protein bindingTubulin beta-4B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-4B chainHomo sapiens (human)
GTP bindingTubulin beta-4B chainHomo sapiens (human)
GTPase activityTubulin beta-3 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-3 chainHomo sapiens (human)
protein bindingTubulin beta-3 chainHomo sapiens (human)
GTP bindingTubulin beta-3 chainHomo sapiens (human)
peptide bindingTubulin beta-3 chainHomo sapiens (human)
metal ion bindingTubulin beta-3 chainHomo sapiens (human)
netrin receptor bindingTubulin beta-3 chainHomo sapiens (human)
GTPase activityTubulin beta-2A chainHomo sapiens (human)
protein bindingTubulin beta-2A chainHomo sapiens (human)
metal ion bindingTubulin beta-2A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-2A chainHomo sapiens (human)
GTP bindingTubulin beta-2A chainHomo sapiens (human)
molecular_functionTubulin beta-8 chainHomo sapiens (human)
GTPase activityTubulin beta-8 chainHomo sapiens (human)
metal ion bindingTubulin beta-8 chainHomo sapiens (human)
GTP bindingTubulin beta-8 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-8 chainHomo sapiens (human)
molecular_functionTubulin alpha-3E chainHomo sapiens (human)
protein bindingTubulin alpha-3E chainHomo sapiens (human)
hydrolase activityTubulin alpha-3E chainHomo sapiens (human)
metal ion bindingTubulin alpha-3E chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-3E chainHomo sapiens (human)
GTP bindingTubulin alpha-3E chainHomo sapiens (human)
structural molecule activityTubulin alpha-1A chainHomo sapiens (human)
protein bindingTubulin alpha-1A chainHomo sapiens (human)
hydrolase activityTubulin alpha-1A chainHomo sapiens (human)
identical protein bindingTubulin alpha-1A chainHomo sapiens (human)
protein-containing complex bindingTubulin alpha-1A chainHomo sapiens (human)
metal ion bindingTubulin alpha-1A chainHomo sapiens (human)
protein heterodimerization activityTubulin alpha-1A chainHomo sapiens (human)
GTP bindingTubulin alpha-1A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1A chainHomo sapiens (human)
structural molecule activityTubulin alpha-1C chainHomo sapiens (human)
protein bindingTubulin alpha-1C chainHomo sapiens (human)
hydrolase activityTubulin alpha-1C chainHomo sapiens (human)
metal ion bindingTubulin alpha-1C chainHomo sapiens (human)
GTP bindingTubulin alpha-1C chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1C chainHomo sapiens (human)
molecular_functionTubulin beta-6 chainHomo sapiens (human)
GTPase activityTubulin beta-6 chainHomo sapiens (human)
protein bindingTubulin beta-6 chainHomo sapiens (human)
metal ion bindingTubulin beta-6 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-6 chainHomo sapiens (human)
GTP bindingTubulin beta-6 chainHomo sapiens (human)
GTPase activityTubulin beta-2B chainHomo sapiens (human)
protein bindingTubulin beta-2B chainHomo sapiens (human)
metal ion bindingTubulin beta-2B chainHomo sapiens (human)
protein heterodimerization activityTubulin beta-2B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-2B chainHomo sapiens (human)
GTP bindingTubulin beta-2B chainHomo sapiens (human)
GTPase activityTubulin beta-1 chainHomo sapiens (human)
metal ion bindingTubulin beta-1 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-1 chainHomo sapiens (human)
GTP bindingTubulin beta-1 chainHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
GTPase activityTubulin beta-4A chainHomo sapiens (human)
calcium ion bindingTubulin beta-4A chainHomo sapiens (human)
protein bindingTubulin beta-4A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-4A chainHomo sapiens (human)
GTP bindingTubulin beta-4A chainHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
GTPase activityTubulin beta chainHomo sapiens (human)
structural molecule activityTubulin beta chainHomo sapiens (human)
protein bindingTubulin beta chainHomo sapiens (human)
protein domain specific bindingTubulin beta chainHomo sapiens (human)
ubiquitin protein ligase bindingTubulin beta chainHomo sapiens (human)
GTPase activating protein bindingTubulin beta chainHomo sapiens (human)
MHC class I protein bindingTubulin beta chainHomo sapiens (human)
protein-containing complex bindingTubulin beta chainHomo sapiens (human)
metal ion bindingTubulin beta chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta chainHomo sapiens (human)
GTP bindingTubulin beta chainHomo sapiens (human)
hydrolase activityTubulin alpha-3C chainHomo sapiens (human)
metal ion bindingTubulin alpha-3C chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-3C chainHomo sapiens (human)
GTP bindingTubulin alpha-3C chainHomo sapiens (human)
double-stranded RNA bindingTubulin alpha-1B chainHomo sapiens (human)
GTPase activityTubulin alpha-1B chainHomo sapiens (human)
structural molecule activityTubulin alpha-1B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
protein bindingTubulin alpha-1B chainHomo sapiens (human)
GTP bindingTubulin alpha-1B chainHomo sapiens (human)
ubiquitin protein ligase bindingTubulin alpha-1B chainHomo sapiens (human)
protein bindingTubulin alpha-4A chainHomo sapiens (human)
hydrolase activityTubulin alpha-4A chainHomo sapiens (human)
protein kinase bindingTubulin alpha-4A chainHomo sapiens (human)
metal ion bindingTubulin alpha-4A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
GTP bindingTubulin alpha-4A chainHomo sapiens (human)
double-stranded RNA bindingTubulin beta-4B chainHomo sapiens (human)
GTPase activityTubulin beta-4B chainHomo sapiens (human)
protein bindingTubulin beta-4B chainHomo sapiens (human)
MHC class I protein bindingTubulin beta-4B chainHomo sapiens (human)
metal ion bindingTubulin beta-4B chainHomo sapiens (human)
unfolded protein bindingTubulin beta-4B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-4B chainHomo sapiens (human)
GTP bindingTubulin beta-4B chainHomo sapiens (human)
GTPase activityTubulin beta-3 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-3 chainHomo sapiens (human)
protein bindingTubulin beta-3 chainHomo sapiens (human)
GTP bindingTubulin beta-3 chainHomo sapiens (human)
peptide bindingTubulin beta-3 chainHomo sapiens (human)
metal ion bindingTubulin beta-3 chainHomo sapiens (human)
netrin receptor bindingTubulin beta-3 chainHomo sapiens (human)
GTPase activityTubulin beta-2A chainHomo sapiens (human)
protein bindingTubulin beta-2A chainHomo sapiens (human)
metal ion bindingTubulin beta-2A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-2A chainHomo sapiens (human)
GTP bindingTubulin beta-2A chainHomo sapiens (human)
molecular_functionTubulin beta-8 chainHomo sapiens (human)
GTPase activityTubulin beta-8 chainHomo sapiens (human)
metal ion bindingTubulin beta-8 chainHomo sapiens (human)
GTP bindingTubulin beta-8 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-8 chainHomo sapiens (human)
molecular_functionTubulin alpha-3E chainHomo sapiens (human)
protein bindingTubulin alpha-3E chainHomo sapiens (human)
hydrolase activityTubulin alpha-3E chainHomo sapiens (human)
metal ion bindingTubulin alpha-3E chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-3E chainHomo sapiens (human)
GTP bindingTubulin alpha-3E chainHomo sapiens (human)
structural molecule activityTubulin alpha-1A chainHomo sapiens (human)
protein bindingTubulin alpha-1A chainHomo sapiens (human)
hydrolase activityTubulin alpha-1A chainHomo sapiens (human)
identical protein bindingTubulin alpha-1A chainHomo sapiens (human)
protein-containing complex bindingTubulin alpha-1A chainHomo sapiens (human)
metal ion bindingTubulin alpha-1A chainHomo sapiens (human)
protein heterodimerization activityTubulin alpha-1A chainHomo sapiens (human)
GTP bindingTubulin alpha-1A chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1A chainHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
structural molecule activityTubulin alpha-1C chainHomo sapiens (human)
protein bindingTubulin alpha-1C chainHomo sapiens (human)
hydrolase activityTubulin alpha-1C chainHomo sapiens (human)
metal ion bindingTubulin alpha-1C chainHomo sapiens (human)
GTP bindingTubulin alpha-1C chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin alpha-1C chainHomo sapiens (human)
molecular_functionTubulin beta-6 chainHomo sapiens (human)
GTPase activityTubulin beta-6 chainHomo sapiens (human)
protein bindingTubulin beta-6 chainHomo sapiens (human)
metal ion bindingTubulin beta-6 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-6 chainHomo sapiens (human)
GTP bindingTubulin beta-6 chainHomo sapiens (human)
GTPase activityTubulin beta-2B chainHomo sapiens (human)
protein bindingTubulin beta-2B chainHomo sapiens (human)
metal ion bindingTubulin beta-2B chainHomo sapiens (human)
protein heterodimerization activityTubulin beta-2B chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-2B chainHomo sapiens (human)
GTP bindingTubulin beta-2B chainHomo sapiens (human)
GTPase activityTubulin beta-1 chainHomo sapiens (human)
metal ion bindingTubulin beta-1 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-1 chainHomo sapiens (human)
GTP bindingTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (59)

Processvia Protein(s)Taxonomy
nucleusTubulin beta-4A chainHomo sapiens (human)
cytosolTubulin beta-4A chainHomo sapiens (human)
microtubuleTubulin beta-4A chainHomo sapiens (human)
axonemeTubulin beta-4A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-4A chainHomo sapiens (human)
internode region of axonTubulin beta-4A chainHomo sapiens (human)
neuronal cell bodyTubulin beta-4A chainHomo sapiens (human)
myelin sheathTubulin beta-4A chainHomo sapiens (human)
intercellular bridgeTubulin beta-4A chainHomo sapiens (human)
extracellular exosomeTubulin beta-4A chainHomo sapiens (human)
mitotic spindleTubulin beta-4A chainHomo sapiens (human)
microtubuleTubulin beta-4A chainHomo sapiens (human)
cytoplasmTubulin beta-4A chainHomo sapiens (human)
extracellular regionTubulin beta chainHomo sapiens (human)
nucleusTubulin beta chainHomo sapiens (human)
nuclear envelope lumenTubulin beta chainHomo sapiens (human)
cytoplasmTubulin beta chainHomo sapiens (human)
cytosolTubulin beta chainHomo sapiens (human)
cytoskeletonTubulin beta chainHomo sapiens (human)
microtubuleTubulin beta chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta chainHomo sapiens (human)
azurophil granule lumenTubulin beta chainHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleTubulin beta chainHomo sapiens (human)
cell bodyTubulin beta chainHomo sapiens (human)
membrane raftTubulin beta chainHomo sapiens (human)
intercellular bridgeTubulin beta chainHomo sapiens (human)
extracellular exosomeTubulin beta chainHomo sapiens (human)
mitotic spindleTubulin beta chainHomo sapiens (human)
protein-containing complexTubulin beta chainHomo sapiens (human)
cytoplasmTubulin beta chainHomo sapiens (human)
microtubuleTubulin beta chainHomo sapiens (human)
nucleusTubulin alpha-3C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-3C chainHomo sapiens (human)
microtubuleTubulin alpha-3C chainHomo sapiens (human)
cytoplasmTubulin alpha-3C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
microtubuleTubulin alpha-1B chainHomo sapiens (human)
cytoplasmic microtubuleTubulin alpha-1B chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
microtubuleTubulin alpha-1B chainHomo sapiens (human)
cytoplasmTubulin alpha-1B chainHomo sapiens (human)
extracellular regionTubulin alpha-4A chainHomo sapiens (human)
cytosolTubulin alpha-4A chainHomo sapiens (human)
cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
microtubuleTubulin alpha-4A chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
extracellular exosomeTubulin alpha-4A chainHomo sapiens (human)
cytoplasmTubulin alpha-4A chainHomo sapiens (human)
microtubuleTubulin alpha-4A chainHomo sapiens (human)
extracellular regionTubulin beta-4B chainHomo sapiens (human)
nucleusTubulin beta-4B chainHomo sapiens (human)
cytosolTubulin beta-4B chainHomo sapiens (human)
cytoskeletonTubulin beta-4B chainHomo sapiens (human)
microtubuleTubulin beta-4B chainHomo sapiens (human)
axonemal microtubuleTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-4B chainHomo sapiens (human)
azurophil granule lumenTubulin beta-4B chainHomo sapiens (human)
intercellular bridgeTubulin beta-4B chainHomo sapiens (human)
extracellular exosomeTubulin beta-4B chainHomo sapiens (human)
mitotic spindleTubulin beta-4B chainHomo sapiens (human)
extracellular vesicleTubulin beta-4B chainHomo sapiens (human)
microtubuleTubulin beta-4B chainHomo sapiens (human)
cytoplasmTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-3 chainHomo sapiens (human)
nucleusTubulin beta-3 chainHomo sapiens (human)
microtubuleTubulin beta-3 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-3 chainHomo sapiens (human)
lamellipodiumTubulin beta-3 chainHomo sapiens (human)
filopodiumTubulin beta-3 chainHomo sapiens (human)
axonTubulin beta-3 chainHomo sapiens (human)
dendriteTubulin beta-3 chainHomo sapiens (human)
growth coneTubulin beta-3 chainHomo sapiens (human)
neuronal cell bodyTubulin beta-3 chainHomo sapiens (human)
intercellular bridgeTubulin beta-3 chainHomo sapiens (human)
extracellular exosomeTubulin beta-3 chainHomo sapiens (human)
cell peripheryTubulin beta-3 chainHomo sapiens (human)
mitotic spindleTubulin beta-3 chainHomo sapiens (human)
microtubuleTubulin beta-3 chainHomo sapiens (human)
cytoplasmTubulin beta-3 chainHomo sapiens (human)
nucleusTubulin beta-2A chainHomo sapiens (human)
microtubuleTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2A chainHomo sapiens (human)
intercellular bridgeTubulin beta-2A chainHomo sapiens (human)
extracellular exosomeTubulin beta-2A chainHomo sapiens (human)
mitotic spindleTubulin beta-2A chainHomo sapiens (human)
extracellular vesicleTubulin beta-2A chainHomo sapiens (human)
cytoplasmTubulin beta-2A chainHomo sapiens (human)
microtubuleTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-8 chainHomo sapiens (human)
intercellular bridgeTubulin beta-8 chainHomo sapiens (human)
extracellular exosomeTubulin beta-8 chainHomo sapiens (human)
mitotic spindleTubulin beta-8 chainHomo sapiens (human)
meiotic spindleTubulin beta-8 chainHomo sapiens (human)
microtubuleTubulin beta-8 chainHomo sapiens (human)
cytoplasmTubulin beta-8 chainHomo sapiens (human)
nucleusTubulin alpha-3E chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-3E chainHomo sapiens (human)
microtubuleTubulin alpha-3E chainHomo sapiens (human)
cytoplasmTubulin alpha-3E chainHomo sapiens (human)
condensed chromosomeTubulin alpha-1A chainHomo sapiens (human)
nucleusTubulin alpha-1A chainHomo sapiens (human)
cytosolTubulin alpha-1A chainHomo sapiens (human)
microtubuleTubulin alpha-1A chainHomo sapiens (human)
axonemal microtubuleTubulin alpha-1A chainHomo sapiens (human)
plasma membraneTubulin alpha-1A chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1A chainHomo sapiens (human)
neuromuscular junctionTubulin alpha-1A chainHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleTubulin alpha-1A chainHomo sapiens (human)
recycling endosomeTubulin alpha-1A chainHomo sapiens (human)
extracellular exosomeTubulin alpha-1A chainHomo sapiens (human)
microtubuleTubulin alpha-1A chainHomo sapiens (human)
cytoplasmTubulin alpha-1A chainHomo sapiens (human)
nucleusTubulin alpha-1C chainHomo sapiens (human)
microtubuleTubulin alpha-1C chainHomo sapiens (human)
cytoplasmic microtubuleTubulin alpha-1C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1C chainHomo sapiens (human)
vesicleTubulin alpha-1C chainHomo sapiens (human)
membrane raftTubulin alpha-1C chainHomo sapiens (human)
microtubuleTubulin alpha-1C chainHomo sapiens (human)
cytoplasmTubulin alpha-1C chainHomo sapiens (human)
nucleusTubulin beta-6 chainHomo sapiens (human)
microtubuleTubulin beta-6 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-6 chainHomo sapiens (human)
intercellular bridgeTubulin beta-6 chainHomo sapiens (human)
extracellular exosomeTubulin beta-6 chainHomo sapiens (human)
mitotic spindleTubulin beta-6 chainHomo sapiens (human)
cytoplasmTubulin beta-6 chainHomo sapiens (human)
microtubuleTubulin beta-6 chainHomo sapiens (human)
nucleusTubulin beta-2B chainHomo sapiens (human)
microtubuleTubulin beta-2B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2B chainHomo sapiens (human)
intercellular bridgeTubulin beta-2B chainHomo sapiens (human)
mitotic spindleTubulin beta-2B chainHomo sapiens (human)
Schaffer collateral - CA1 synapseTubulin beta-2B chainHomo sapiens (human)
microtubuleTubulin beta-2B chainHomo sapiens (human)
cytoplasmTubulin beta-2B chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-1 chainHomo sapiens (human)
intercellular bridgeTubulin beta-1 chainHomo sapiens (human)
extracellular exosomeTubulin beta-1 chainHomo sapiens (human)
mitotic spindleTubulin beta-1 chainHomo sapiens (human)
microtubuleTubulin beta-1 chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nucleusTubulin beta-4A chainHomo sapiens (human)
cytosolTubulin beta-4A chainHomo sapiens (human)
microtubuleTubulin beta-4A chainHomo sapiens (human)
axonemeTubulin beta-4A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-4A chainHomo sapiens (human)
internode region of axonTubulin beta-4A chainHomo sapiens (human)
neuronal cell bodyTubulin beta-4A chainHomo sapiens (human)
myelin sheathTubulin beta-4A chainHomo sapiens (human)
intercellular bridgeTubulin beta-4A chainHomo sapiens (human)
extracellular exosomeTubulin beta-4A chainHomo sapiens (human)
mitotic spindleTubulin beta-4A chainHomo sapiens (human)
microtubuleTubulin beta-4A chainHomo sapiens (human)
cytoplasmTubulin beta-4A chainHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionTubulin beta chainHomo sapiens (human)
nucleusTubulin beta chainHomo sapiens (human)
nuclear envelope lumenTubulin beta chainHomo sapiens (human)
cytoplasmTubulin beta chainHomo sapiens (human)
cytosolTubulin beta chainHomo sapiens (human)
cytoskeletonTubulin beta chainHomo sapiens (human)
microtubuleTubulin beta chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta chainHomo sapiens (human)
azurophil granule lumenTubulin beta chainHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleTubulin beta chainHomo sapiens (human)
cell bodyTubulin beta chainHomo sapiens (human)
membrane raftTubulin beta chainHomo sapiens (human)
intercellular bridgeTubulin beta chainHomo sapiens (human)
extracellular exosomeTubulin beta chainHomo sapiens (human)
mitotic spindleTubulin beta chainHomo sapiens (human)
protein-containing complexTubulin beta chainHomo sapiens (human)
cytoplasmTubulin beta chainHomo sapiens (human)
microtubuleTubulin beta chainHomo sapiens (human)
nucleusTubulin alpha-3C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-3C chainHomo sapiens (human)
microtubuleTubulin alpha-3C chainHomo sapiens (human)
cytoplasmTubulin alpha-3C chainHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
microtubule cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
microtubuleTubulin alpha-1B chainHomo sapiens (human)
cytoplasmic microtubuleTubulin alpha-1B chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1B chainHomo sapiens (human)
microtubuleTubulin alpha-1B chainHomo sapiens (human)
cytoplasmTubulin alpha-1B chainHomo sapiens (human)
extracellular regionTubulin alpha-4A chainHomo sapiens (human)
cytosolTubulin alpha-4A chainHomo sapiens (human)
cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
microtubuleTubulin alpha-4A chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-4A chainHomo sapiens (human)
extracellular exosomeTubulin alpha-4A chainHomo sapiens (human)
cytoplasmTubulin alpha-4A chainHomo sapiens (human)
microtubuleTubulin alpha-4A chainHomo sapiens (human)
extracellular regionTubulin beta-4B chainHomo sapiens (human)
nucleusTubulin beta-4B chainHomo sapiens (human)
cytosolTubulin beta-4B chainHomo sapiens (human)
cytoskeletonTubulin beta-4B chainHomo sapiens (human)
microtubuleTubulin beta-4B chainHomo sapiens (human)
axonemal microtubuleTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-4B chainHomo sapiens (human)
azurophil granule lumenTubulin beta-4B chainHomo sapiens (human)
intercellular bridgeTubulin beta-4B chainHomo sapiens (human)
extracellular exosomeTubulin beta-4B chainHomo sapiens (human)
mitotic spindleTubulin beta-4B chainHomo sapiens (human)
extracellular vesicleTubulin beta-4B chainHomo sapiens (human)
microtubuleTubulin beta-4B chainHomo sapiens (human)
cytoplasmTubulin beta-4B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-3 chainHomo sapiens (human)
nucleusTubulin beta-3 chainHomo sapiens (human)
microtubuleTubulin beta-3 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-3 chainHomo sapiens (human)
lamellipodiumTubulin beta-3 chainHomo sapiens (human)
filopodiumTubulin beta-3 chainHomo sapiens (human)
axonTubulin beta-3 chainHomo sapiens (human)
dendriteTubulin beta-3 chainHomo sapiens (human)
growth coneTubulin beta-3 chainHomo sapiens (human)
neuronal cell bodyTubulin beta-3 chainHomo sapiens (human)
intercellular bridgeTubulin beta-3 chainHomo sapiens (human)
extracellular exosomeTubulin beta-3 chainHomo sapiens (human)
cell peripheryTubulin beta-3 chainHomo sapiens (human)
mitotic spindleTubulin beta-3 chainHomo sapiens (human)
microtubuleTubulin beta-3 chainHomo sapiens (human)
cytoplasmTubulin beta-3 chainHomo sapiens (human)
nucleusTubulin beta-2A chainHomo sapiens (human)
microtubuleTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2A chainHomo sapiens (human)
intercellular bridgeTubulin beta-2A chainHomo sapiens (human)
extracellular exosomeTubulin beta-2A chainHomo sapiens (human)
mitotic spindleTubulin beta-2A chainHomo sapiens (human)
extracellular vesicleTubulin beta-2A chainHomo sapiens (human)
cytoplasmTubulin beta-2A chainHomo sapiens (human)
microtubuleTubulin beta-2A chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-8 chainHomo sapiens (human)
intercellular bridgeTubulin beta-8 chainHomo sapiens (human)
extracellular exosomeTubulin beta-8 chainHomo sapiens (human)
mitotic spindleTubulin beta-8 chainHomo sapiens (human)
meiotic spindleTubulin beta-8 chainHomo sapiens (human)
microtubuleTubulin beta-8 chainHomo sapiens (human)
cytoplasmTubulin beta-8 chainHomo sapiens (human)
nucleusTubulin alpha-3E chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-3E chainHomo sapiens (human)
microtubuleTubulin alpha-3E chainHomo sapiens (human)
cytoplasmTubulin alpha-3E chainHomo sapiens (human)
condensed chromosomeTubulin alpha-1A chainHomo sapiens (human)
nucleusTubulin alpha-1A chainHomo sapiens (human)
cytosolTubulin alpha-1A chainHomo sapiens (human)
microtubuleTubulin alpha-1A chainHomo sapiens (human)
axonemal microtubuleTubulin alpha-1A chainHomo sapiens (human)
plasma membraneTubulin alpha-1A chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1A chainHomo sapiens (human)
neuromuscular junctionTubulin alpha-1A chainHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleTubulin alpha-1A chainHomo sapiens (human)
recycling endosomeTubulin alpha-1A chainHomo sapiens (human)
extracellular exosomeTubulin alpha-1A chainHomo sapiens (human)
microtubuleTubulin alpha-1A chainHomo sapiens (human)
cytoplasmTubulin alpha-1A chainHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleusTubulin alpha-1C chainHomo sapiens (human)
microtubuleTubulin alpha-1C chainHomo sapiens (human)
cytoplasmic microtubuleTubulin alpha-1C chainHomo sapiens (human)
microtubule cytoskeletonTubulin alpha-1C chainHomo sapiens (human)
vesicleTubulin alpha-1C chainHomo sapiens (human)
membrane raftTubulin alpha-1C chainHomo sapiens (human)
microtubuleTubulin alpha-1C chainHomo sapiens (human)
cytoplasmTubulin alpha-1C chainHomo sapiens (human)
nucleusTubulin beta-6 chainHomo sapiens (human)
microtubuleTubulin beta-6 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-6 chainHomo sapiens (human)
intercellular bridgeTubulin beta-6 chainHomo sapiens (human)
extracellular exosomeTubulin beta-6 chainHomo sapiens (human)
mitotic spindleTubulin beta-6 chainHomo sapiens (human)
cytoplasmTubulin beta-6 chainHomo sapiens (human)
microtubuleTubulin beta-6 chainHomo sapiens (human)
nucleusTubulin beta-2B chainHomo sapiens (human)
microtubuleTubulin beta-2B chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-2B chainHomo sapiens (human)
intercellular bridgeTubulin beta-2B chainHomo sapiens (human)
mitotic spindleTubulin beta-2B chainHomo sapiens (human)
Schaffer collateral - CA1 synapseTubulin beta-2B chainHomo sapiens (human)
microtubuleTubulin beta-2B chainHomo sapiens (human)
cytoplasmTubulin beta-2B chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-1 chainHomo sapiens (human)
intercellular bridgeTubulin beta-1 chainHomo sapiens (human)
extracellular exosomeTubulin beta-1 chainHomo sapiens (human)
mitotic spindleTubulin beta-1 chainHomo sapiens (human)
microtubuleTubulin beta-1 chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (230)

Assay IDTitleYearJournalArticle
AID1692983Antiproliferative activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 3210-(4-Phenylpiperazine-1-carbonyl)acridin-9(10H)-ones and related compounds: Synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID1426445Antiproliferative activity against human K562 cells after 48 hrs by Alamar blue dye based neubauer hemocytometer method2017Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2
N-Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization.
AID1426446Inhibition of porcine tubulin polymerization after 45 mins by turbidometric method2017Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2
N-Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization.
AID1262236Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Synthesis and antiproliferativeactivity of new vinca alkaloids containing an α,β-unsaturated aromatic side chain.
AID1656398Inhibition of tubulin in Schizosaccharomyces pombe TY27 overexpressing GFP-HSET assessed as growth restoring activity incubated for 3 days by agar plate-based method2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Kolavenic acid analog restores growth in HSET-overproducing fission yeast cells and multipolar mitosis in MDA-MB-231 human cells.
AID1492876Inhibition of tubulin polymerization (unknown origin) preincubated for 10 mins followed by GTP addition measured after 20 mins by Coomassie blue staining based SDS-PAGE analysis2017European journal of medicinal chemistry, Dec-01, Volume: 141Triazolopyridinyl-acrylonitrile derivatives as antimicrotubule agents: Synthesis, in vitro and in silico characterization of antiproliferative activity, inhibition of tubulin polymerization and binding thermodynamics.
AID1262235Cytotoxicity against human KB cells after 72 hrs by SRB assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Synthesis and antiproliferativeactivity of new vinca alkaloids containing an α,β-unsaturated aromatic side chain.
AID1692984Inhibition of porcine brain tubulin polymerization assessed as reduction in tubulin assembly at 37 degreeC measured after 40 mins in presence of GTP by turbidimetric analysis2021Bioorganic & medicinal chemistry letters, 01-15, Volume: 3210-(4-Phenylpiperazine-1-carbonyl)acridin-9(10H)-ones and related compounds: Synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID1262237Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Synthesis and antiproliferativeactivity of new vinca alkaloids containing an α,β-unsaturated aromatic side chain.
AID1262238Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Synthesis and antiproliferativeactivity of new vinca alkaloids containing an α,β-unsaturated aromatic side chain.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347141qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1147722Antitumor activity against mouse Ridgeway osteogenic sarcoma cells allografted in mouse at 0.1 to 0.35 mg/kg/day, ip1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1124077Antitumor activity against mouse P388/S cells allografted in CD2F1 mouse assessed as increase in host lifespan at 1.80 mg/kg, ip administered on days 1, 5 and 91979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID1147743Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in life span at 0.4 mg/kg/day, ip administered from day 1 to day 9 relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID356089Cytotoxicity against human SCL9 cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID329433Toxicity in human HCT116 cells xenografted NCR nu/nu mouse assessed as decrease in neutrophil count in peripheral blood at 2 mg/kg, iv QD for 6 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-13, Volume: 104, Issue:7
Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.
AID1124078Antitumor activity against mouse P388/S cells allografted in CD2F1 mouse assessed as increase in host lifespan at 1.08 mg/kg, ip administered on days 1, 5 and 91979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1147756Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as mean survival time at 1.08 mg/kg/day, ip administered on day 1, 5 and 9 (Rvb = 20.0 days)1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID427296Cytotoxicity against human A549 cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Cytotoxic activity and inhibitory effect on nitric oxide production of triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae).
AID1124069Antitumor activity against mouse P1534 cells allografted in DBA2 mouse assessed as tumor growth inhibition at 0.40 mg/kg, ip administered daily for 8 to 10 days1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID1124067Antitumor activity against mouse P1534 cells allografted in DBA2 mouse assessed as tumor growth inhibition at 0.25 mg/kg, ip administered daily for 8 to 10 days1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID605956Inhibition of pig tubulin polymerization determined after 45 mins at 37 degC by turbidimetric analysis2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
N-benzoylated phenoxazines and phenothiazines: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID621897Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway.
AID427291Cytotoxicity against human ACHN cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Cytotoxic activity and inhibitory effect on nitric oxide production of triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae).
AID621989Inhibition of bovine brain tubulin polymerization at 10 uM after 1 hrs by fluorescence assay2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway.
AID774567Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Jul, Volume: 65Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity.
AID398902Cytotoxicity against human HCT8 cells1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID342598Induction of beta2-tubulin alkylation in human M21 cells at 50 nM by Western blot analysis2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
AID1124075Toxicity in iv dosed mouse assessed as lethality1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID427299Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Cytotoxic activity and inhibitory effect on nitric oxide production of triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae).
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1147782Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as mean survival time at 0.648 mg/kg/day, ip administered on day 5, 9 and 13 (Rvb = 20.0 days)1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147792Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as increase in life span at 0.648 mg/kg/day, ip administered on day 5, 9 and 13 measured for 56 days relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1124093Toxicity in CD2F1 mouse allografted with mouse P388/VCR cells at 3.00 mg/kg, ip administered on days 1, 5 and 91979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID1124079Antitumor activity against mouse P388/S cells allografted in CD2F1 mouse assessed as increase in host lifespan at 0.648 mg/kg, ip administered on days 1, 5 and 91979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID774565Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Jul, Volume: 65Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID427300Cytotoxicity against human 142BR cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Cytotoxic activity and inhibitory effect on nitric oxide production of triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae).
AID1147739Antitumor activity against mouse P388 cells allografted in mouse assessed as survival at 0.4 mg/kg/day administered from day 1 to day 91978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147780Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as mean survival time at 1.8 mg/kg/day, ip administered on day 5, 9 and 13 (Rvb = 20.0 days)1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID329432Toxicity in human HCT116 cells xenografted NCR nu/nu mouse assessed as decrease in neutrophil count in peripheral blood at 20 mg/kg, iv QD for 6 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-13, Volume: 104, Issue:7
Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.
AID274785Inhibition of tubulin polymerization in porcine brain2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID356091Cytotoxicity against human NUGC4 cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID669361Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Spectaflavoside A, a new potent iron chelating dimeric flavonol glycoside from the rhizomes of Zingiber spectabile Griff.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID427293Cytotoxicity against human C32 cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Cytotoxic activity and inhibitory effect on nitric oxide production of triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae).
AID427292Cytotoxicity against human A375 cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Cytotoxic activity and inhibitory effect on nitric oxide production of triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID621899Cytotoxicity against human UACC903 cells after 48 hrs by MTS assay2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway.
AID1147764Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as mean survival time at 3 mg/kg/day, ip administered on day 1, 5 and 9 (Rvb = 20.0 days)1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147790Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as increase in life span at 1.8 mg/kg/day, ip administered on day 5, 9 and 13 measured for 56 days relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147730Antitumor activity against mouse P388 cells allografted in mouse assessed as survival at 2.7 mg/kg/day after 1 day1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID774568Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Jul, Volume: 65Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity.
AID669356Antiproliferative activity against human DU145 cells after 48 hrs by MTS assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Spectaflavoside A, a new potent iron chelating dimeric flavonol glycoside from the rhizomes of Zingiber spectabile Griff.
AID1147783Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as mean survival time at 0.389 mg/kg/day, ip administered on day 5, 9 and 13 (Rvb = 20.0 days)1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147750Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as mean survival time at 0.389 mg/kg/day, ip administered on day 1, 5 and 9 (Rvb = 20.0 days)1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147781Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as mean survival time at 1.08 mg/kg/day, ip administered on day 5, 9 and 13 (Rvb = 20.0 days)1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147779Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as mean survival time at 3 mg/kg/day, ip administered on day 5, 9 and 13 (Rvb = 20.0 days)1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147789Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as increase in life span at 3 mg/kg/day, ip administered on day 5, 9 and 13 measured for 56 days relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID611267Antiproliferative activity against human K562 cells after 48 hrs by hemocytometer2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID1124092Toxicity in CD2F1 mouse allografted with mouse P388/S cells at 3.00 mg/kg, ip administered on days 1, 5 and 91979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID1147727Acute toxicity in ip dosed mouse1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1124068Antitumor activity against mouse P1534 cells allografted in DBA2 mouse assessed as tumor growth inhibition at 0.30 mg/kg, ip administered daily for 8 to 10 days1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID347582Inhibition of pig brain tubulin polymerization after 30 mins by turbidimetric assay2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1124089Antitumor activity against mouse P388/VCR cells allografted in B6D2F1 mouse assessed as increase in host lifespan at 1.20 mg/kg, ip administered on days 1, 5 and 91979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID770279Induction of microtubule depolymerization in rat REF52 cells at 0.1 uM after 30 mins by fluorescence assay2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Enantioselective effects of (+)- and (-)-citronellal on animal and plant microtubules.
AID1147766Toxicity in ip dosed mouse allografted with mouse p388 cells after 1 day1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID303684Antiproliferative activity against human K562 cells after 48 hrs2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1147771Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as increase in life span at 1.08 mg/kg/day, ip administered on day 1, 5 and 9 measured for 56 days relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147793Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as increase in life span at 0.389 mg/kg/day, ip administered on day 5, 9 and 13 measured for 56 days relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID329414Antitumor activity against human HCT116 cells xenografted into NCR nu/nu mouse at 0.45 mg/kg, ip dosed in q2-3dX6 schedule relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-13, Volume: 104, Issue:7
Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.
AID669357Antiproliferative activity against human SK-MEL-5 cells after 48 hrs by MTS assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Spectaflavoside A, a new potent iron chelating dimeric flavonol glycoside from the rhizomes of Zingiber spectabile Griff.
AID1124076Antitumor activity against mouse P388/VCR cells allografted in CD2F1 mouse assessed as increase in host lifespan at 1.08 mg/kg, ip administered on days 1, 5 and 91979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID1124084Antitumor activity against mouse P388/VCR cells allografted in CD2F1 mouse assessed as increase in host lifespan at 1.80 mg/kg, ip administered on days 1, 5 and 91979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID494521Inhibition of tubulin polymerization in human K562 cells2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by anthracenone-based oxime derivatives.
AID1124090Antitumor activity against mouse P388/VCR cells allografted in B6D2F1 mouse assessed as increase in host lifespan at 0.90 mg/kg, ip administered on days 1, 5 and 91979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID342600Inhibition of nuclear translocation of thioredoxin-1 from cytosol in human M21 cells at 50 nM after 16 hrs by immunocytofluorescence2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
AID356090Cytotoxicity against human KATO III cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID1147741Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in life span at 0.9 mg/kg/day, ip administered from day 1 to day 9 relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147765Toxicity in ip dosed mouse allografted with mouse p388 cells administered from day 1 to day 91978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1124106Mitotic arrest in CHO cells assessed as increase in cell accumulation at 0.2 ug/ml1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID1147744Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in life span at 0.27 mg/kg/day, ip administered from day 1 to day 9 relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID329429Toxicity in human HCT116 cells xenografted NCR nu/nu mouse assessed as loss of body weight at 2 mg/kg, iv QD for 6 days2007Proceedings of the National Academy of Sciences of the United States of America, Feb-13, Volume: 104, Issue:7
Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.
AID1147772Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as increase in life span at 0.648 mg/kg/day, ip administered on day 1, 5 and 9 measured for 56 days relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147726Antitumor activity against mouse Gardner lymphosarcoma cell allografted in mouse at 0.1 to 0.35 mg/kg/day, ip1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID52530In vitro concentration required to kill 50% of COLO 320 human colorectal carcinoma cell line2002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1124066Antitumor activity against mouse P1534 cells allografted in DBA2 mouse assessed as tumor growth inhibition at 0.20 mg/kg, ip administered daily for 8 to 10 days1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID494502Inhibition of pig brain tubulin polymerization after 30 mins by turbidimetry2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID774564Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Jul, Volume: 65Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity.
AID611278Inhibition of pig brain tubulin polymerization after 30 mins by turbidimetry analysis2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID356086Cytotoxicity against human SCL cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID427297Cytotoxicity against human Huh-7D12 cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Cytotoxic activity and inhibitory effect on nitric oxide production of triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae).
AID101492In vitro inhibitory concentration against human chronic myelogenous leukemia K562 cell growth2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1147758Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in life span at 4 mg/kg/day, ip after 1 day1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147763Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as mean survival time at 1.8 mg/kg/day, ip administered on day 1, 5 and 9 (Rvb = 20.0 days)1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID303685Inhibition of porcine brain tubulin polymerization2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1147734Antitumor activity against mouse P1534(J) cells allografted in mouse assessed as tumor growth inhibition at 0.35 mg/kg/day, ip administered from day 1 to day 9 relative to unreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID347581Antiproliferative activity against human K562 cells after 48 hrs2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID329420Antitumor activity against human MDA-MB-435 cells xenografted into NCR nu/nu mouse at 0.7 mg/kg, ip dosed in q3-4dX4 schedule relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-13, Volume: 104, Issue:7
Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.
AID427298Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Cytotoxic activity and inhibitory effect on nitric oxide production of triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae).
AID268887Antiproliferative activity against human NCI60 cell line measured as mean graph midpoint2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
AID669359Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Spectaflavoside A, a new potent iron chelating dimeric flavonol glycoside from the rhizomes of Zingiber spectabile Griff.
AID356087Cytotoxicity against human SCL6 cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID1124091Antitumor activity against mouse P388/VCR cells allografted in B6D2F1 mouse assessed as increase in host lifespan at 0.60 mg/kg, ip administered on days 1, 5 and 91979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID342597Induction of beta2-tubulin alkylation in human M21 cells at 2 times GI50 by Western blot analysis2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
AID1147769Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as increase in life span at 3 mg/kg/day, ip administered on day 1, 5 and 9 measured for 56 days relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID669355Antiproliferative activity against human A549 cells after 48 hrs by MTS assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Spectaflavoside A, a new potent iron chelating dimeric flavonol glycoside from the rhizomes of Zingiber spectabile Griff.
AID329431Toxicity in human HCT116 cells xenografted NCR nu/nu mouse assessed as decrease in neutrophil count in bone marrow at 2 mg/kg, iv QD for 6 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-13, Volume: 104, Issue:7
Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.
AID1124085Antitumor activity against mouse P388/VCR cells allografted in CD2F1 mouse assessed as increase in host lifespan at 0.648 mg/kg, ip administered on days 1, 5 and 91979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID1124108Mitotic arrest in CHO cells assessed as increase in cell accumulation at 0.002 ug/ml1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID669362Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Spectaflavoside A, a new potent iron chelating dimeric flavonol glycoside from the rhizomes of Zingiber spectabile Griff.
AID274784Antiproliferative activity against human K562 cell line2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1147791Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as increase in life span at 1.08 mg/kg/day, ip administered on day 5, 9 and 13 measured for 56 days relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID774566Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay2013European journal of medicinal chemistry, Jul, Volume: 65Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity.
AID1147738Antitumor activity against mouse P388 cells allografted in mouse assessed as survival at 4 mg/kg/day after 1 day1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147752Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as mean survival time at 0.648 mg/kg/day, ip administered on day 1, 5 and 9 (Rvb = 20.0 days)1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1124107Mitotic arrest in CHO cells assessed as increase in cell accumulation at 0.02 ug/ml1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID1147736Toxicity in ip dosed mouse allografted with mouse P1534(J) cells administered from day 1 to day 91978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID427295Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Cytotoxic activity and inhibitory effect on nitric oxide production of triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae).
AID159533In vitro inhibition of maximum porcine tubulin assembly rate after 20 min at 37 degrees C2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID669358Antiproliferative activity against human BxPC3 cells after 48 hrs by MTS assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Spectaflavoside A, a new potent iron chelating dimeric flavonol glycoside from the rhizomes of Zingiber spectabile Griff.
AID1147757Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in life span at 6 mg/kg/day, ip after 1 day1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID100389In vitro concentration required to kill 50% of LNCaP human prostate cancer cell line2002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.
AID1147773Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as increase in life span at 0.389 mg/kg/day, ip administered on day 1, 5 and 9 measured for 56 days relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID621896Cytotoxicity against human HT-29 cells after 48 hrs by MTS assay2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway.
AID329428Toxicity in human HCT116 cells xenografted NCR nu/nu mouse assessed as loss of body weight at 20 mg/kg, iv QD for 6 days2007Proceedings of the National Academy of Sciences of the United States of America, Feb-13, Volume: 104, Issue:7
Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.
AID329430Toxicity in human HCT116 cells xenografted NCR nu/nu mouse assessed as decrease in neutrophil count in bone marrow at 20 mg/kg, iv QD for 6 days relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Feb-13, Volume: 104, Issue:7
Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.
AID1147742Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in life span at 0.6 mg/kg/day, ip administered from day 1 to day 9 relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147755Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in life span at 9 mg/kg/day, ip after 1 day1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1124109Displacement of [3H]VLB from tubulin in pig brain by competitive assay1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Structure-activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvinblastine amide (vindesine) sulfates.
AID669360Antiproliferative activity against human HT-29 cells after 48 hrs by MTS assay2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Spectaflavoside A, a new potent iron chelating dimeric flavonol glycoside from the rhizomes of Zingiber spectabile Griff.
AID1147759Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in life span at 2.7 mg/kg/day, ip after 1 day1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID356088Cytotoxicity against human SCL37'6 cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID621898Cytotoxicity against human A549 cells after 48 hrs by MTS assay2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway.
AID494520Cell growth inhibition of human K562 cells after 48 hrs2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by anthracenone-based oxime derivatives.
AID605844Antiproliferative activity against human K562 cells after 48 hrs by hemocytometric analysis2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
N-benzoylated phenoxazines and phenothiazines: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID494501Antiproliferative activity against human K562 cells after 48 hrs2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety.
AID1147770Antitumor activity against mouse B16 cells allografted in B6D2F1 mouse assessed as increase in life span at 1.8 mg/kg/day, ip administered on day 1, 5 and 9 measured for 56 days relative to untreated control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID1147825Acute toxicity in rat1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.
AID398901Cytotoxicity against human A549 cells1997Journal of natural products, Jun, Volume: 60, Issue:6
Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID208675In vitro concentration required to kill 50% of T47D human breast ductal carcinoma cell line2002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (4.35)18.7374
1990's1 (2.17)18.2507
2000's13 (28.26)29.6817
2010's22 (47.83)24.3611
2020's8 (17.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.02 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index58.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other41 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]